Q4 2022 13F Holders as of 31 Dec 2022
-
Type / Class
-
Equity / Common Stock, $0.00001 par value
-
Shares outstanding
-
274,772,727
-
Total 13F shares
-
19,375,255
-
Share change
-
+5,401,271
-
Total reported value
-
$43,785,515
-
Put/Call ratio
-
68%
-
Price per share
-
$2.26
-
Number of holders
-
51
-
Value change
-
+$12,385,904
-
Number of buys
-
31
-
Number of sells
-
23
Institutional Holders of Taysha Gene Therapies, Inc. - Common Stock, $0.00001 par value (TSHA) as of Q4 2022
As of 31 Dec 2022 Taysha Gene Therapies, Inc. - Common Stock, $0.00001 par value (TSHA) had 51 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions held a total of 19,375,255 shares of stock of the company.
Largest 10 holders included FMR LLC, Nantahala Capital Management, LLC, VANGUARD GROUP INC, TYBOURNE CAPITAL MANAGEMENT (HK) LTD, Artal Group S.A., Laurion Capital Management LP, FRANKLIN RESOURCES INC, Sands Capital Ventures, LLC, BlackRock Inc., and Alphabet Inc..
This table shows 51 institutional shareholders of the security as of 31 Dec 2022.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.